CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache society

CONCLUSIONS: Most of the respondents recommended CGRPmAbs to patients with ≥ 2 preventive failures, followed by ≥ 1. The MMD threshold ranged mostly from ≥ 4 to ≥ 10. The concern for costs was raised as a major limiting factor for prescribing CGRPmAbs.PMID:38491415 | PMC:PMC10941476 | DOI:10.1186/s10194-024-01737-y

Source: Pain Physician - March 16, 2024 Category: Anesthesiology Authors: Tsubasa Takizawa Keiko Ihara Narumi Watanabe Ryo Takemura Nobuyuki Takahashi Naoki Miyazaki Mamoru Shibata Keisuke Suzuki Noboru Imai Norihiro Suzuki Koichi Hirata Takao Takeshima Jin Nakahara Source Type: research